The Liverpool Drug Interaction Group (based at the University of Liverpool, UK), in collaboration with the University Hospital of Basel (Switzerland) and Radboud UMC (Netherlands), have produced various materials in PDF format to aid the use of experimental agents in the treatment of COVID-19.
Please check this site regularly for updates and additional information.
UPDATED – Atazanavir and tocilizumab added as new COVID-therapies; anticonvulsants and antifungals added as new comedications.
Details of the nature of drug interactions with experimental COVID-19 therapies (atazanavir, lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, nitazoxanide, ribavirin, tocilizumab) and many comedication classes are given in the PDF below. Please use your browser’s “find” function to search for drug names. [Note: Darunavir/cobicistat has been removed from the PDF following a statement by Janssen regarding lack of evidence to support the use of darunavir-based treatments for COVID-19.]
Updated 20 March 2020
UPDATED – Atazanavir and tocilizumab added as new COVID-therapies; anticonvulsants and antifungals added as new comedications.
A summary of interactions with experimental COVID-19 therapies (atazanavir, lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, nitazoxanide, ribavirin, tocilizumab) and over 400 comedications are shown. The nature of the interactions for many of the comedications are available in the “Detailed recommendations for interactions…” PDF above. Please use your browser’s “find” function to search for drug names within the PDF. [Note: Darunavir/cobicistat has been removed from the PDF following a statement by Janssen regarding lack of evidence to support the use of darunavir-based treatments for COVID-19.]
Updated 20 March 2020
UPDATED - Further details on crushing lopinavir/ritonavir tablets added.
Advice for administering experimental COVID-19 therapies to patients who cannot swallow is given in the pdf below.
Updated 27 March 2020
This document explains how we have evaluated the drug-drug interaction risk of the experimental COVID-19 therapies and gives details of their metabolism, interaction potential and cardiac effects.
Updated 25 March 2020
The Liverpool Drug Interaction Group was established in 1999 by members of the Department of Pharmacology at the University of Liverpool to provide a freely available drug-drug interaction resource for drugs used to treat HIV infection. Since then, our activity has expanded to included drug interaction information for the treatment of hepatitis B infection, hepatitis C infection, primary biliary cholangitis and various cancers (in collaboration with Radboud UMC, Netherlands). These interaction resources can be found at: